SLC5A2 and diabetes mellitus: Analysis of 13 placebo-controlled trials with median follow-upsranging from 0.8 to 4.2 years (n = 74 804 patients with diabetes) found thatin the reported 167 DKA events, SGLT2 inhibitors were associated with anincreased risk of DKA versus control (reported rate in placebo groups of 0.2events per 1000 patient years; RR for SGLT2 inhibitors of 2.12, 95% CI1.49-3.04).48 Subgroup analyses showed a larger relative effectamong patients aged ≥60 years and those with longer use of SGLT2 inhibitors(>52 weeks).118